Improving technologies of treatment of psoriasis patients is a serious medical and social problem whose significance is primarily determined by unreliability of existing drug therapies and torpidity of the pathological process. The article presents the authors’ own data on the use of combined ultraviolet therapy UVB 311 nm/UVA and low doses of methotrexate for treatment of patients with severe forms of psoriasis. Material and methods. The study included 126 patients aged 32 to 68 years. All patients were diagnosed with widespread severe psoriasis whose psoriatic area and severity index (PASI) was more than 20. The following clinical forms of psoriasis were present: vulgar (43.1%), exudative (33.1%), and seborrheic (23.8%). The patients were divided, using simple randomization, into three subgroups: a subgroup A (n=46) whose patients received combined UVB 311 nm/UVA at 320—400 nm and low-dose methotrexate (7.5—10.0 mg per week, the course consisted of 6 cycles); a subgroup B (n=41) whose patients received combined UVB 311 nm/UVA at 320—400 nm; a subgroup C (n=39) whose patients received methotrexate at standard doses (20.0—25.0 mg/week, the course consisted of 6—8 cycles). Results. A reduction in the PASI values was more pronounced in the group where the combined method was used. Application of combined ultraviolet therapy and methotrexate demonstrated the best results in patients with psoriasis vulgaris. The efficacy was moderate in the case of exudative and seborrheic psoriasis. Investigation of the PASI dynamics using the dispersion analysis demonstrated a high statistical relationship of the effect of the combined method on a reduction of the index for p=0.0041 and the efficacy for various forms of psoriasis and time of occurrence of the clinically significant effect for p<0.0001, F (3, 357)=188.4. An analysis of the dynamics of the Body Surface Area (BSA) index that reflects the area of lesion without allowance for clinical symptoms also revealed advantages of the combined method. A pattern similar to the objective symptomatology was observed with respect to the dynamics of itching reduction. Comprehensive assessment of the dermatology life quality index (DLQI) indicates a more pronounced positive effect of the combined method on the daily activity and psycho-emotional status of patients. Conclusions. The combined treatment of patients with psoriasis is characterized by a high safety profile as evidenced by the absence of clinically significant adverse events (such as thrombocytopenia and leukopenia), the negative dynamics of the content of hepatic transaminases and serum creatinine that improves significantly the patient compliance. The high therapeutic and preventive efficacy of the combined method as well as its safety make it possible to recommend the developed procedure for wide application in practice by dermatovenereologists.